A study of belumosudil in children with chronic graft versus host disease (schoolROCK)

Trial Identifier: DFI17893
Sponsor: Sanofi
Collaborator:
Meiji Seika Pharma Co., Ltd.
Start Date: December 2025
Primary Completion Date: February 2031
Study Completion Date: February 2031
Condition: Graft Versus Host Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BELGIUM Gent, BELGIUM, 9000
BELGIUM Leuven, BELGIUM, 3000
CHINA Shanghai, CHINA
CHINA Shenzhen, CHINA, 518026
CHINA Suzhou, CHINA, 215006
FRANCE MARSEILLE, FRANCE, 13385
FRANCE Paris, FRANCE, 75019
GERMANY Berlin, GERMANY, 13353
ISRAEL Haifa, ISRAEL, 3109601
ISRAEL Jerusalem, ISRAEL, 91120
ISRAEL Tel HaShomer, ISRAEL, 52621
ISRAEL Tel-Aviv, ISRAEL, 64239
ITALY, Roma Roma, ITALY, 00165
NETHERLANDS Utrecht, NETHERLANDS, 3584 CS
SPAIN Barcelona, SPAIN, 08035
SPAIN, Catalunya [Cataluña] Esplugues de Llobregat, Catalunya [Cataluña], SPAIN, 08950
SPAIN, Madrid, Comunidad de Madrid, Madrid, Comunidad de, SPAIN, 28009
UNITED KINGDOM, Newcastle upon Tyne Newcastle upon Tyne, UNITED KINGDOM, NE1 4LP
UNITED STATES, New York New York, UNITED STATES, 10065-6007
UNITED STATES, Texas Houston, Texas, UNITED STATES, 77030